Congenital aniridia is a panocular disorder that is typically characterized by iris hypoplasia
and aniridia-associated keratopathy (AAK). AAK results in the progressive loss of corneal
transparency and thereby loss of vision. Currently, there is no approved therapy to delay or
prevent its progression, and clinical management is challenging because of phenotypic
variability and high risk of complications after interventions; however, new insights into the
molecular pathogenesis of AAK may help improve its management. Here, we review the …